We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Pfizer's $40M Bid for BIND Therapeutics
News

Pfizer's $40M Bid for BIND Therapeutics

Pfizer's $40M Bid for BIND Therapeutics
News

Pfizer's $40M Bid for BIND Therapeutics

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Pfizer's $40M Bid for BIND Therapeutics"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BIND Therapeutics, Inc. has announced that Pfizer Inc. prevailed at a Section 363 auction to purchase substantially all of BIND's assets. The winning bid of $40 million, subject to U.S. Bankruptcy Court approval for which a hearing is scheduled to take place on July 27, 2016, was selected as the highest and best bid. NanoCarrier Co., Ltd. has been selected as the back-up bidder. The Company plans to disclose additional terms of its agreement with Pfizer upon Court approval. 

This comes after BIND received two bids that were qualified to participate in the Court authorized auction. The bids were in addition to Pfizer Inc.'s initial stalking horse bid of approximately $20 millionunder Section 363 of the U.S. Bankruptcy Code.

BIND initiated voluntary Chapter 11 bankruptcy protection on May 1, 2016 and conducted a sale of assets, pursuant to Section 363 of the Bankruptcy Code, during an auction held on July 25 and 26, 2016. 


 

Advertisement